多中心试验:妊娠期熊去氧胆酸与二甲双胍治疗妊娠期糖尿病以减少糖尿病影响(GUARD)的随机对照试验方案
GUARD试验为双组、开放标签、多中心随机对照试验,计划在英格兰和威尔士七家NHS信托机构招募158名妊娠期糖尿病孕妇,随机接受熊去氧胆酸或二甲双胍治疗至分娩,主要评估熊去氧胆酸相比二甲双胍改善血糖的疗效,并评估母胎结局及熊去氧胆酸的可接受性。
要点
- 妊娠期糖尿病增加母婴产科和新生儿并发症风险,二甲双胍为最常用一线药物治疗。
- 熊去氧胆酸目前不用于妊娠期糖尿病治疗,但可改善2型糖尿病血糖控制及妊娠期胆汁淤积症胎儿血脂谱。
- GUARD试验主要结局为评估熊去氧胆酸相比二甲双胍改善妊娠期糖尿病孕妇血糖水平的疗效。
核心结论
- 该试验有潜力为妊娠期糖尿病孕妇确定一种潜在新治疗方法。
- 若试验成功,未来将设计大型多中心试验,以研究如何将决策个体化,识别哪些女性对熊去氧胆酸比替代方案反应更有效,从而改善母婴结局。
研究设计与样本
- 双组、开放标签、多中心、随机对照试验。
- 计划在英格兰和威尔士七家NHS信托机构招募共158名孕妇。
- 纳入标准为妊娠24+0至30+6周经口服葡萄糖耐量试验诊断为妊娠期糖尿病且需要药物干预的孕妇。
- 同意入组者随机接受二甲双胍或熊去氧胆酸,每日服用直至分娩。
- 采集母体和新生儿血样以评估治疗对母体血糖控制及母体和新生儿脂质代谢的影响,并评估母胎结局及熊去氧胆酸相比二甲双胍的可接受性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Each year in the UK, approximately 35,000 women develop gestational diabetes mellitus (GDM). The condition increases the risk of obstetric and neonatal complications for mother and child, including preeclampsia, preterm birth, and large for gestational age babies. Biochemical consequences include maternal hyperglycemia, neonatal hypoglycemia, and dyslipidemia. Metformin is the most commonly used firstline pharmacological treatment. However, there are concerns about its widespread use during pregnancy, due to its limited efficacy and potential safety concerns. Therefore, there is a need for additional therapies that improve both maternal-fetal glucose and lipid metabolism. Ursodeoxycholic acid (UDCA) is not currently used for treatment for GDM. However, it can improve glucose control in type 2 diabetes, and it improves fetal lipid profiles in gestational cholestasis. Consequentially, it is hypothesized that treatment with UDCA for women with GDM may improve both maternal metabolism and neonatal outcomes. The primary outcome of this trial is to assess the efficacy of UDCA compared with metformin to improve glucose levels in women with GDM. METHODS: The trial is a two-armed, open-label, multi-center, randomized controlled trial. Women are eligible if they have been diagnosed with GDM by an oral glucose tolerance test between 24 + 0 and 30 + 6 weeks' gestation, and if they require pharmacological intervention. In total, 158 pregnant women will be recruited across seven NHS Trusts in England and Wales. Women who consent will be recruited and randomized to either metformin or UDCA, which will be taken daily until the birth of their baby. Maternal and neonatal blood samples will be taken to evaluate the impact of the treatments on maternal glucose control, and maternal and neonatal lipid metabolism. Maternal and fetal outcomes will be evaluated, and acceptability of UDCA compared with metformin will be assessed. DISCUSSION: This trial has the potential to identify a potential new treatment for women with GDM. If successful, a future large multi-center trial will be designed to investigate where decisions can be personalized to identify which women will respond more effectively to UDCA than alternatives to improve maternal and baby outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04407650.
引用
- Lovell H, Mitchell A, Ovadia C, et al. A multi-centered trial investigating gestational treatment with ursodeoxycholic acid compared to metformin to reduce effects of diabetes mellitus (GUARD): a randomized controlled trial protocol. Trials. 2022. PMID: 35854327. doi:10.1186/s13063-022-06462-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。